J.P. Morgan Maintains a Hold Rating on Amgen (AMGN)


In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Amgen (AMGN). The company’s shares closed last Tuesday at $235.95.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.5% and a 57.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $268.81.

See today’s analyst top recommended stocks >>

The company has a one-year high of $264.97 and a one-year low of $177.05. Currently, Amgen has an average volume of 2.51M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts